MBIO today
$0.35-$0.02 (-4.30%)close Nov 20, 2026Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $0.56
Key levels
Resistance$0.49
Resistance$0.43
Support$0.35
Latest news & SEC filings
ProductMindBio Therapeutics hits product development milestone, announces private placement
EarningsMustang Bio Posts Q3 2026 Financials
All MBIO news →About Mustang Bio
Mustang Bio develops experimental treatments for hard-to-treat cancers, working at the clinical testing stage. Its programs center on engineered immune cells and modified viruses aimed at solid tumors, including aggressive brain cancers such as glioblastoma and high-grade astrocytoma. The company licenses these candidates from research centers including City of Hope and Nationwide Children's Hospital, and it is mostly owned by Fortress Biotech.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
MUSTANG BIO, INC. (MBIO)
What Is the Price Target for MBIO?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is MBIO a Buy or Sell Right Now?
Test your own strategy on MBIO
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on MBIO with SEPT’s own market data.
Start Free Trial →Is MBIO Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$2.40
7
Moat Score
NONE
3/9
Piotroski Score
-31.4
Altman Z-Score
What Is Smart Money Doing with MBIO?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →MBIO Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
98.99%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for MBIO
PREVIEWRecent off-exchange (dark pool) prints for MBIO: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:03:28 | $0.30 | 4,983 | $$1K | BUY |
| 22:03:18 | $0.29 | 4,876 | $$1K | BUY |
| 22:03:00 | $0.29 | 4,983 | $$1K | BUY |
| 21:46:38 | $0.30 | 5,000 | $$1K | BUY |
| 21:28:22 | $0.29 | 1,700 | $$500 | SELL |
5 dark pool trades shown · $$6K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MUSTANG BIO, INC. (MBIO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →MBIO — frequently asked questions
What is MBIO stock price today?
MUSTANG BIO, INC. (MBIO) is at $0.35, down 4.30% (-$0.02) at the Nov 20, 2026 close.
Why is MBIO stock moving today?
Latest MBIO news — Nov 16, 2026: MindBio Therapeutics hits product development milestone, announces private placement · Nov 7, 2026: Mustang Bio Posts Q3 2026 Financials
Did MBIO beat earnings?
MBIO last reported on Aug 5, 2026: EPS -$0.16 vs -$140.00 expected — a beat of 99.9%.
What are MBIO support and resistance levels?
Support: $0.35. Resistance: $0.43, $0.49, $0.56.
What are insiders doing with MBIO?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on MBIO?
Nov 16, 2026: MindBio Therapeutics hits product development milestone, announces private placement · Nov 7, 2026: Mustang Bio Posts Q3 2026 Financials